Hydrocortisone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1952
- First approval year
- 1952
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Hydrocortisone
- Molecular weight
- 362.47
- Structure (SMILES)
- C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
- acetasol hc
- Acetasol hc
- acticort
- Acticort
- aeroseb hc
- Aeroseb-hc
- ala cort
- ala scalp
- Ala-cort
- Ala-scalp
- alkindi
- Alkindi
- alkindi sprinkle
- Alkindi sprinkle
- alphaderm
- Alphaderm
- anflam
- Anflam
- anucort hc
- Anucort-hc
- anugesic hc
- Anugesic hc
- anusol hc
- Anusol hc
- anusol plus hc
And 190 more, listed on the interactive page.
- 10 mg hc 325 mg apap
- acetasol hc component hydrocortisone
- ACETASOL HC COMPONENT HYDROCORTISONE
- alphaderm component hydrocortisone
- ALPHADERM COMPONENT HYDROCORTISONE
- anucort hc
- Anucort-HC
- calmurid hc component hydrocortisone
- CALMURID HC COMPONENT HYDROCORTISONE
- cipro hc
- Cipro HC
- cor oticin
- Cor-oticin
- cortenema
- Cortenema
- cortisol
- Cortisol
- dual release hydrocortisone plenadren
- flexicort
- FLEXICORT
- hidrocortisona
- Hidrocortisona
- hydrocortisone
- Hydrocortisone
- hydrocortisone (LEO 80190)
And 75 more, listed on the interactive page.
- CAS registry numbers
- 50-23-7
- ChEMBL ID
- CHEMBL389621
- InChIKey
- JYGXADMDTFJGBT-VWUMJDOOSA-N
- PubChem compound IDs
- 5754
- FDA ingredient codes (UNII)
- WI4X0X7BPJ
- A01AC03
- A07EA02
- C05AA01
- D07AA02
- D07XA01
- H02AB09
- R01AD60
- S01BA02
- S01CB03
- S02BA01
Sources for recorded values
- 5492
- 1007334
- Applicant
- PHARMACIA AND UPJOHN
- Approval date
- 15 Dec 1952
- Application number
- NDA008697
- Status
- Authorised
- Status date
- 3 Nov 2011
- Authorisation date
- 3 Nov 2011
- Approved indications
- Treatment of adrenal insufficiency in adults.
- Product number
- EMEA/H/C/002185
- Authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Adrenal Insufficiency
European medicines record
- Patents
- 5
- Designations
- 3
- Earliest recorded loss of exclusivity
- 23 Feb 2043
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- cortisol
- Type
- Metabolite
- Drug name stem
- -cort-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- Mineralocorticoid receptor
- Action
- Agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Agonist
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Affinity units
- pIC50
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
- Action type
- Binding
- Target
- <i>GPR33</i>
- Gene symbol
- <i>GPR33</i>
- Action
- Binding
- Action type
- Binding
- Target
- GPR33
- Gene symbol
- GPR33
- Protein identifier
- Q49SQ1
- Median affinity
- 7.92
- Affinity units
- pKd
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Leukemia, Erythroblastic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000218
- Subject identifier
- D004915
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Monocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000221
- Subject identifier
- D007948
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia, Myelomonocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000223
- Subject identifier
- D015479
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Pancreatitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000278
- Subject identifier
- D010195
- Condition
- Crohn Disease
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Wounds and Injuries
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Leukemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Psoriasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Skin Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
And 79 more, listed on the interactive page.
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000275
- Condition identifier
- EFO_0000278
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000565
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000612
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000701
- Condition identifier
- EFO_0000714
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000729
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001072
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001358
- Condition identifier
- EFO_0001379
- Condition identifier
- EFO_0001422
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002609
- Condition identifier
- EFO_0003046
- Highest recorded phase
- 2
And 243 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 596
- Reporting signal score
- 722.753
- Event
- adrenal insufficiency
- Reports
- 183
- Reporting signal score
- 364.332
- Event
- adrenocortical insufficiency acute
- Reports
- 80
- Reporting signal score
- 246.7
- Event
- alopecia
- Reports
- 592
- Reporting signal score
- 704.407
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 423
- Reporting signal score
- 1,617.63
- Event
- arthralgia
- Reports
- 618
- Reporting signal score
- 230.097
- Event
- arthropathy
- Reports
- 497
- Reporting signal score
- 843.119
- Event
- blister
- Reports
- 223
- Reporting signal score
- 241.464
- Event
- condition aggravated
- Reports
- 612
- Reporting signal score
- 315.038
- Event
- discomfort
- Reports
- 444
- Reporting signal score
- 867.344
- Event
- drug hypersensitivity
- Reports
- 1,441
- Reporting signal score
- 1,716.67
- Event
- drug intolerance
- Reports
- 556
- Reporting signal score
- 611.013
- Event
- duodenal ulcer perforation
- Reports
- 225
- Reporting signal score
- 761.963
- Event
- fatigue
- Reports
- 873
- Reporting signal score
- 181.113
- Event
- febrile bone marrow aplasia
- Reports
- 289
- Reporting signal score
- 901.531
- Event
- febrile neutropenia
- Reports
- 326
- Reporting signal score
- 291.681
- Event
- folliculitis
- Reports
- 121
- Reporting signal score
- 261.331
- Event
- frequent bowel movements
- Reports
- 115
- Reporting signal score
- 166.643
- Event
- glossodynia
- Reports
- 492
- Reporting signal score
- 1,395.27
- Event
- hand deformity
- Reports
- 476
- Reporting signal score
- 1,527.08
- Event
- helicobacter infection
- Reports
- 230
- Reporting signal score
- 663.763
- Event
- hepatic enzyme increased
- Reports
- 456
- Reporting signal score
- 610.253
- Event
- hip arthroplasty
- Reports
- 145
- Reporting signal score
- 269.779
- Event
- hypersensitivity
- Reports
- 618
- Reporting signal score
- 556.308
- Event
- hypofibrinogenaemia
- Reports
- 99
- Reporting signal score
- 336.581
And 25 more, listed on the interactive page.
- NCT00001521
- NCT00519818
- NCT00621985
- NCT01735617
- NCT01771328
- NCT01859312
- NCT02096510
- NCT03019614
- NCT03062280
- NCT03548246
- NCT03760835
- NCT04536662
- NCT05063994
- NCT00002471
- NCT00002494
- NCT00002552
- NCT00002700
- NCT00002757
- NCT00003215
- NCT00003728
- NCT00006455
- NCT00133991
- NCT00392834
- NCT00002704
- NCT00002744
And 154 more, listed on the interactive page.
- Route
- Topical
- How often
- 2-4 times daily
Conditions of use
- Apply a thin film to affected area
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 94.83
- Calculated partition coefficient (ALogP)
- 1.78
- Calculated partition coefficient (XLogP)
- 1.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 26
- Molecular formula
- C21H30O5
- Monoisotopic mass
- 362.20932405
- Natural product
- Yes
- 0009-0012
- 0009-0031
- 0009-0044
- 0115-1696
- 0115-1697
- 0115-1700
- 0168-0015
- 0168-0020
- 0168-0080
- 0168-0146
- 0178-0455
- 0187-5104
- 0316-0126
- 0316-0128
- 0316-0186
- 0316-0193
- 0472-0321
- 0713-0849
- 0713-0851
- 0781-6218
- 0904-7188
- 10631-407
- 21922-065
- 23155-926
- 24208-631
And 144 more, listed on the interactive page.
- Recorded assays
- 4,892
- Active assays
- 113
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
These details could not be displayed.
Related records
Trials (352)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- 506U78 in Treating Patients With Refractory Hematologic Cancer
- A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
- A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
- A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
- A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
- A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics
- A Pilot Trial of Pediatric Liver Transplantation Without Steroids
- A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis
- A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
- A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
- A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
- A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Approved for (33)
- Adrenal gland disorder
- Adrenocortical insufficiency
- Asthma
- Atopic conjunctivitis
- Atopic eczema
- Bursitis
- Cancer
- Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Congenital adrenal hyperplasia
- Crohn disease
- Dermatitis
- Endocrine system disorder
- Exanthem
- Eye disorder
- Hemorrhoid
- Herpes labialis
- Herpes simplex infectious disease
- Juvenile idiopathic arthritis
- Leukemia
- Lymphoma
In development for (128)
- Acute erythroid leukemia Phase 3
- Acute graft versus host disease Phase 2
- Acute kidney injury Phase 3
- Acute leukemia of ambiguous lineage Phase 3
- Acute lymphoblastic leukemia Phase 3
- Acute megakaryoblastic leukemia Phase 3
- Acute monocytic leukemia Phase 3
- Acute myeloblastic leukemia without maturation Phase 3
- Acute myeloid leukemia Phase 3
- Acute myeloid leukemia by FAB classification Phase 3
- Acute myelomonocytic leukemia M4 Phase 3
- Acute pancreatitis Phase 2
- Acute respiratory distress syndrome Phase 3
- Acute respiratory failure Phase 3
- Adrenal cortex carcinoma Phase 2
- Alcohol dependence Phase 3
- Alcoholic hepatitis Phase 3
- Allergic rhinitis Phase 1
- Alopecia areata Phase 3
- Anaplastic large cell lymphoma Phase 1
Other linked conditions (41)
- Anemia
- Ankylosing spondylitis
- Anterior uveitis
- Autoimmune encephalitis
- Autoimmune hemolytic anemia
- Autoimmune hepatitis
- Autoimmune pancreatitis
- Biliary atresia
- Chronic obstructive pulmonary disease
- Chronic rhinosinusitis
- Crohn's colitis
- de Quervain disease
- Depressive disorder
- Diabetes mellitus
- Dry eye syndrome
- Eosinophilic esophagitis
- Frozen shoulder
- Glaucoma
- Hepatitis B virus infection
- Hepatitis C virus infection